The CGRP peptide exerts its influence by binding to a CGRP receptor and activating intracellular signalling pathways, such as the cAMP (cyclic adenosine monophosphate) pathway.1 By interacting with second-order neurons passing on a nociceptive signal, interacting with smooth muscle cells lining the cerebral artery, and interacting with inflammatory mediators such as mast cells, there are several potential points of intervention where anti-CGRP therapies might arrest migraine pathology.1,2
Read more about targeted therapies in migraine, such as triptans and CGRP medications
Related content
The pathology of ischaemic stroke is complex, but commonly involves the formation of a clot that travels in the blood to or within the brain and becomes lodged in the blood vessels of the brain (a thromboembolism), which can reduce or block blood flow (an occlusion).
Post-stroke fatigue is an under-recognized NPS, which healthcare professionals should anticipate in patients.
Emotional lability describes episodes of involuntary and uncontrollable crying and/or laughing, outside of socially appropriate circumstances and when it is incongruent with the patient’s emotional state.